HealthRx.com

Side Effects Adele Publicly Discussed (and What They Match in the Clinical Literature)

By
Published Updated Last reviewed
Medication safety clinical consultation image for Side Effects Adele Publicly Discussed (and What They Match in the Clinical Literature)
Clinical image for Side Effects Adele Publicly Discussed (and What They Match in the Clinical Literature) Image: HealthRX.com clinical image

What Adele Has Actually Said

Between 2020 and 2022, Adele addressed her roughly 100-pound weight loss in several high-profile interviews. In her October 2021 British Vogue cover story, she described exercising two to three times a day, initially as an anxiety-management tool rather than a weight-loss strategy. "It was because of my anxiety," she told the magazine. "Working out, I would just feel better."

In the same period, she described bouts of intense exhaustion and acknowledged feeling destabilized by the public's reaction to her appearance. During her October 2021 Oprah interview on CBS, she reiterated that the transformation was driven by exercise and mental-health management, not a specific drug or crash diet. She has referenced the Sirtfood Diet, a calorie-restricted plan centered on foods high in sirtuin-activating polyphenols.

At no point has Adele confirmed the use of semaglutide, liraglutide, tirzepatide, or any other GLP-1 receptor agonist. Public speculation about GLP-1 involvement has appeared across tabloid and social media, but it remains exactly that: speculation.

The Speculation in Context

GLP-1 receptor agonists gained mainstream visibility starting in late 2022, roughly a year after Adele's weight loss was most discussed. Semaglutide (branded as Ozempic for type 2 diabetes, Wegovy for weight management) received FDA approval for chronic weight management in June 2021. Tirzepatide (Zepbound) followed in November 2023.

Adele's most visible weight change predates the cultural moment when GLP-1 prescriptions surged. That timeline makes the speculation less plausible on its face, though it does not rule anything out. The HealthRX.com Medical Team takes no position on whether Adele used any medication. The clinical exercise below is hypothetical and educational.

Symptoms Adele Described: A Clinical Crosswalk

At a glance

  • Confirmed by Adele: anxiety, exhaustion, body-image distress during rapid weight loss
  • Medication status: GLP-1 use is publicly speculated, not confirmed; Adele credits exercise and the Sirtfood Diet
  • Clinical overlap: several symptoms Adele described do appear in the GLP-1 adverse-event literature, but they also appear in any significant caloric-deficit scenario
  • Key distinction: correlation with a drug's side-effect profile does not imply causation, especially when the drug's use is unconfirmed

Fatigue and Exhaustion

Adele told British Vogue she experienced significant fatigue during her weight-loss period. Fatigue is a commonly reported adverse event in GLP-1 receptor agonist trials. In the STEP 1 trial (semaglutide 2.4 mg vs. placebo in adults with obesity), fatigue was reported by approximately 11% of participants in the treatment arm versus 5% in the placebo group.

The mechanism is straightforward. GLP-1 agonists reduce caloric intake through appetite suppression, delayed gastric emptying, and central satiety signaling. Rapid caloric reduction from any cause, whether pharmacological or behavioral, can produce fatigue via glycogen depletion, micronutrient gaps, and disrupted sleep architecture. A restrictive diet like the Sirtfood plan (which can drop below 1,000 kcal/day in its initial phase) would produce comparable fatigue without any drug involvement.

Anxiety

Adele has been open about longstanding anxiety, predating her weight loss. She told Oprah that exercise became her primary coping mechanism. In the GLP-1 clinical literature, anxiety is not a primary labeled adverse event. The FDA prescribing information for Wegovy lists psychiatric events including suicidal ideation under warnings, but anxiety as an independent adverse event appears at rates similar to placebo in phase 3 data.

A 2023 pharmacovigilance analysis published in JAMA Internal Medicine examined FDA Adverse Event Reporting System data for semaglutide and liraglutide. Anxiety-related reports existed but did not reach a statistically disproportionate signal relative to background rates. The HealthRX.com Medical Team notes that anxiety during rapid body-composition change is well-documented independent of any drug, driven by hormonal shifts (particularly cortisol and leptin), disrupted identity, and public scrutiny.

Gastrointestinal Complaints

Adele has not publicly described nausea, vomiting, or diarrhea. This is worth noting because GI events are the single most common adverse-event class for GLP-1 agonists. In STEP 1, nausea affected 44% of the semaglutide group versus 17% on placebo. Diarrhea hit 30% vs. 16%. Vomiting occurred in 24% vs. 6%. The SURMOUNT-1 trial for tirzepatide showed a similar GI-dominant side-effect profile.

The absence of any public GI complaints from Adele is not evidence against GLP-1 use (she may simply have chosen not to discuss them), but it is a data point in the public record.

Body-Composition Concerns and Muscle Loss

Adele described feeling physically different in ways that went beyond fat loss. Rapid weight reduction on GLP-1 agonists raises a well-studied concern: lean mass loss. A 2024 analysis in The Lancet Diabetes & Endocrinology found that approximately 25-40% of weight lost on semaglutide 2.4 mg is lean tissue. This ratio is broadly consistent with non-pharmacological caloric restriction, where lean mass typically accounts for 20-30% of total weight lost, though the absolute magnitude is larger with GLP-1s because total weight loss is greater.

The HealthRX.com Medical Team emphasizes that resistance training during any rapid weight-loss intervention (pharmacological or dietary) is the primary tool for preserving muscle mass. Adele's reported exercise regimen, which included strength training with a personal trainer, would be exactly the clinical recommendation for mitigating this risk.

What the HealthRX.com Medical Team Takes Away

This case illustrates a problem the medical community increasingly faces. When a public figure loses a significant amount of weight, the default assumption has shifted toward pharmacological assistance, specifically GLP-1 receptor agonists. That assumption may or may not be correct in any individual case. For Adele, the public record supports a lifestyle-driven explanation, and she has said so repeatedly.

The clinical value of this page is not in resolving speculation. It lies in the crosswalk itself. The symptoms Adele publicly described (fatigue, anxiety, physical destabilization during rapid weight loss) are real clinical phenomena that occur both with and without GLP-1 agonist therapy. Patients considering these medications should understand that the adverse-event profile is dominated by GI effects, with fatigue and mood changes as secondary but documented complaints.

For anyone losing weight rapidly, whether through semaglutide, the Sirtfood Diet, or intensive exercise, the HealthRX.com Medical Team recommends monitoring for:

  • Resting metabolic rate decline (adaptive thermogenesis)
  • Lean mass preservation via DEXA or BIA tracking
  • Micronutrient status (B12, iron, vitamin D are common gaps during caloric restriction)
  • Mental health screening, particularly for anxiety and body dysmorphia during periods of visible physical change

Frequently asked questions

›
›
›
›

References

For More Info Visit HealthRx.com
Visit Now